Cytovale: the overall objective of this contract is to evaluate the impact of the intellisep test on clinical decision-making and its potential to aid in improving sepsis risk stratification and…
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50123C00066
- Awardee
-
Cytovale Inc. UEI TG7HM4HD8594
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $599,551
Award facts
- Contract value 100% obligated
- $599,551.19 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 100 offers Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- San Francisco, CA 94134, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $599,551 |
About this award
This is a $599,551.19 firm-fixed-price contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Cytovale Inc., a small disadvantaged business based in San Francisco, California. The contract is for the Solving the Question of Inflammation or Sepsis Hastily - Decision Impact (SQUISH-DI) study, which aims to evaluate the impact of Cytovale's IntelliSep test on clinical decision-making and sepsis risk stratification. This contract supports Cytovale's expertise in developing and evaluating rapid diagnostic technologies for sepsis detection. It builds upon a previous $9,050,674 cost-sharing contract awarded to Cytovale by ASPR in 2019 to advance the company's biophysical early sepsis diagnostic towards FDA clearance. The SQUISH-DI study contract has a performance period that runs through May 30, 2025 and does not have a set-aside designation.
Description
Cytovale: the overall objective of this contract is to evaluate the impact of the intellisep test on clinical decision-making and its potential to aid in improving sepsis risk stratification and resource utilization. The contract will support the SQU
Quick answers
Who was awarded contract 75A50123C00066?
75A50123C00066 was awarded to Cytovale Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 19, 2023.
How much is contract 75A50123C00066 worth?
The government has obligated $599,551 on 75A50123C00066.
Was contract 75A50123C00066 competed?
The extent of competition for 75A50123C00066 was full and open competition. The government received 100 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award